METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENTA[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE-3-CARBOXYLATE AS Cav1,2 ACTIVATORS
The present disclosure provides for a compound according to formula (I)
The present disclosure provides for a compound according to formula (I)
The present disclosure provides for a compound according to formula (I)
or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.
C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
C07D 221/04 - Ortho- or peri-condensed ring systems
2.
TOTAL MAGNIFICATION CALCULATION OF DIGITAL MICROSCOPE HAVING DIGITAL BINOCULARS AND INTERCHANGEABLE EYEPIECES
A visualization system for use with an ophthalmic microscope having a pair of image sensors includes a first pair and multiple second pairs of interchangeable eyepieces each having a corresponding magnification level and field-of-view (FOV), and digital binoculars in communication with the image sensors. The digital binoculars include a housing configured to connect to the ophthalmic microscope and defining a housing cavity, a pair of annular bases connected to the housing configured to separately engage the first and multiple second pairs of interchangeable eyepieces to provide the FOV, and surrounding a corresponding center axis or designated position, and a pair of micro displays positioned within the housing cavity. Each respective one of the micro displays is arranged on the corresponding center axis or designated position.
A system includes an ophthalmic microscope including a camera and a controller coupled to the camera. The controller configured to receive at least one image from the camera, the at least one image including a representation of an eye of a patient. The controller segments the at least one image using a machine learning model to obtain at least one segmented image including one or more labels of one or more Purkinje images represented in the at least one image. The controller produces an output according to the at least one segmented image. The output may be an estimate location of the visual axis of the eye. The output may include an estimate of an offset between the visual axis and a center of an IOL implanted in the eye. The segmented image may further label the IOL and possibly one or more items of anatomy of the eye.
The invention is directed to an embedded hydrogel contact lens, which comprises an insert sandwiched between two layers of hydrogel materials and can be produced according to a cast molding method including the procedures involving two females halves (FC1 and FC2) and two male halves (BC1 and BC2) and three consequential molding steps involving three molding assemblies: the 1st one formed between FC1 and BC1 for molding an insert; the 2nd one formed between FC1 and BC2 for molding a lens precursor having the molded insert embedded in a layer of a hydrogel material in a way that the front surface of the molded insert merges with the convex surface of the lens precursor; and the 3rd one formed between FC2 and BC2 for molding an embedded hydrogel contact of the invention.
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
B29D 11/00 - Producing optical elements, e.g. lenses or prisms
B29K 83/00 - Use of polymers having silicon, with or without sulfur, nitrogen, oxygen or carbon only, in the main chain, as moulding material
B29K 105/00 - Condition, form or state of moulded material
C08G 77/00 - Macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon, with or without sulfur, nitrogen, oxygen, or carbon
The invention relates to a method for producing embedded hydrogel contact lenses each having an insert that comprises alignment features capable of capable of aligning the insert in depth and radial position in a female mold half during cast molding of an embedded hydrogel contact lens. The alignment features protrude from the front surface, are rotationally symmetric with respect to the central axis of the insert and independently have a shape having a curvature being greater than 2 folds of the curvature of the molding surface so as to minimize contacting area between the alignment features and the molding surface. The use of such an insert can simplify the process for producing embedded hydrogel contact lenses and enable the process to be implemented readily in an automatic production.
B29C 39/02 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor for making articles of definite length, i.e. discrete articles
B29C 39/00 - Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressureApparatus therefor
G02B 1/04 - Optical elements characterised by the material of which they are madeOptical coatings for optical elements made of organic materials, e.g. plastics
6.
KRAS G12C INHIBITOR FOR USE FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER
The present invention relates to a method of treating non-small cell lung cancer (NSCLC) which harbors a KRAS G12C mutation, wherein the method comprises the administration of KRAS G12C inhibitor 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (Compound A), or a pharmaceutically acceptable salt, solvate or hydrate thereof, and a therapeutically effective amount of pembrolizumab; in particular the present invention relates to a method of treating NSCLC wherein the NSCLC expresses at least 1% PD-L1 according to the tumor proportion score (TPS), more particularly the NSCLC expresses at least 50% PD-L1 according to the tumor proportion score (TPS).
A system includes an ophthalmic microscope including first and second illuminator optics configured to emit light onto an eye of a patient. The system further includes a controller coupled to the first and second illuminator optics. The controller is configured to operate in a first mode in which light emitted by the first illuminator optics and light emitted by the second illuminator optics has a first configuration. The controller is configured to operate in a second mode in which the light emitted by the first illuminator optics and the light emitted by the second illuminator optics are configured to enhance visibility of one or more Purkinje images projected onto the eye of the patient by the first illuminator optics relative to the first configuration. Registration of the optical axis of the eye, robotic alignment, and autofocusing may also be performed using Purkinje images.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/113 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining or recording eye movement
A system includes an ophthalmic microscope including a camera and a controller coupled to the camera. The controller configured to receive at least one image from the camera, the at least one image including a representation of an eye of a patient. The controller segments the at least one image using a machine learning model to obtain at least one segmented image including one or more labels of one or more Purkinje images represented in the at least one image. The controller produces an output according to the at least one segmented image. The output may be an estimate location of the visual axis of the eye. The output may include an estimate of an offset between the visual axis and a center of an IOL implanted in the eye. The segmented image may further label the IOL and possibly one or more items of anatomy of the eye.
A visualization system for use with an ophthalmic microscope having a pair of image sensors includes a first pair and multiple second pairs of interchangeable eyepieces each having a corresponding magnification level and field-of-view (FOV), and digital binoculars in communication with the image sensors. The digital binoculars include a housing configured to connect to the ophthalmic microscope and defining a housing cavity, a pair of annular bases connected to the housing configured to separately engage the first and multiple second pairs of interchangeable eyepieces to provide the FOV, and surrounding a corresponding center axis or designated position, and a pair of micro displays positioned within the housing cavity. Each respective one of the micro displays is arranged on the corresponding center axis or designated position.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 9/00 - Medicinal preparations characterised by special physical form
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
11.
PROCESS OF PREPARING REMIBRUTINIB SUBSTANTIALLY FREE OF NITROSAMINE IMPURITY
This invention relates to a new process for preparing N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide (LOU064) drug substance substantially free of nitrosamine impurities as well as new crystalline forms of salt and solvate of LOU064 used in the process. The invention further relates to pharmaceutical composition comprising N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, wherein the composition is substantially free of a nitrosamine impurity, e.g. the nitrosamine impurity N-(3-(6-amino-5-(2(methyl)(nitroso)amino)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide. Pharmaceutical products containing said drug substance and compositions are also disclosed, as well as methods for preparing said drug substance, pharmaceutical compositions and products.
A method for estimating biometric landmark dimensional measurements of a human eye includes, in a possible embodiment, receiving one or more images of the human eye via a host computer. In response to receiving the one or more images, the method includes generating a preliminary set of landmark point locations in the one or more images via the host computer using a deep-learning algorithm, and then refining the preliminary set of landmark point locations using a post-hoc processing routine of the host computer to thereby generate a final set of estimated landmark point locations. Additionally, the biometric landmark dimensional measurements are automatically generated via the host computer using the final set of estimated landmark point locations. A data set is then output that is inclusive of the set of estimated landmark point locations. A host computer that executes instructions from memory to perform the method.
A system includes an ophthalmic microscope including first and second illuminator optics configured to emit light onto an eye of a patient. The system further includes a controller coupled to the first and second illuminator optics. The controller is configured to operate in a first mode in which light emitted by the first illuminator optics and light emitted by the second illuminator optics has a first configuration. The controller is configured to operate in a second mode in which the light emitted by the first illuminator optics and the light emitted by the second illuminator optics are configured to enhance visibility of one or more Purkinje images projected onto the eye of the patient by the first illuminator optics relative to the first configuration. Registration of the optical axis of the eye, robotic alignment, and autofocusing may also be performed using Purkinje images.
An automated production line for the production of ophthalmic lenses comprises:
a production line front end (1) comprising:
a first injection-molding machine (10) and a second injection-molding machine (12)
a casting module (14) comprising
a filling station (144) and a capping station (145);
a stacking module (15) and a curing module (16);
a destacking module (17) and a demolding and delensing module
a production line back end (2) comprising:
an inspection module (21);
Wherein the inspection module comprising a rail system in which self-driving shuttles carrying the inspection cuvettes are arranged on a closed-loop rail, wherein the rail system can be adapted to the available space in the production plant/hall using curves and straight portions in the manner known from a model railway.
The present invention relates to a method of treating non-small cell lung cancer (NSCLC) which harbors a KRAS G12C mutation, wherein the method comprises the administration of a therapeutically effective amount of KRAS G12C inhibitor 1-{6-[(4M)-4-(5-Chloro-6-methyl-5 1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one (Compound A), or a pharmaceutically acceptable salt, solvate or hydrate thereof, a therapeutically effective amount of pembrolizumab, a therapeutically effective amount of pemetrexed and a therapeutically effective amount of platinum therapy; in particular the present invention relates to a method of treating NSCLC wherein the NSCLC expresses at least 1% PD-L1 according to the tumor proportion score (TPS), more particularly wherein the NSCLC expresses less than 50% PD-L1 according to the tumor proportion score (TPS), more particularly wherein the NSCLC expresses PD-L1 1- 49% according to the tumor proportion score (TPS), even more particularly wherein the NSCLC expresses <1% PD-L1 according to the tumor proportion score (TPS).
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AlN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
An ophthalmic surgical instrument for measuring tissues is provided. The instrument includes a handle comprising a distal end and a proximal end, an instrument portion extending from the distal end of the handle, and an outer tube located around the instrument portion. The instrument portion of the surgical instrument further includes a distal end comprising an end effector. The degree of movement of the end effector corresponds to a scale on the handle of the surgical instrument that facilitates the measurement of a tissue during ophthalmic procedures. The movement of the outer tube or the end effector may further facilitate measurement of the tissue.
An ophthalmic surgical instrument for peeling a retinal membrane is provided. The ophthalmic surgical instrument includes a handle, an actuator mounted to the handle, a first loop, and a second loop. The first loop extends outwardly from the handle and comprises a first plurality of protruding features configured to create an internal limiting membrane (ILM) flap in an eye. The second loop extends outwardly from the handle, is positioned within the first loop, and is configured to grasp the ILM flap. The actuator is configured to move the second loop to engage the first loop to grasp the ILM flap.
A mixer attachment for use with a surgical hand piece includes a powder plate configured to contain a solid substance for combining with a liquid substance to form a combined substance. The mixer attachment further includes a plurality of mixing plates configured to mix the solid substance and the liquid substance in the combined substance, the plurality of mixing plates including: one or more channeled plates comprising one or more channels and one or more through holes configured to facilitate turbulent flow of the combined substance during mixing, and one or more flat plates comprising a central opening to direct flow of the combined substance between the one or more channeled plates.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A system for guiding an ophthalmic procedure is disclosed. The system includes a housing assembly with a head unit configured to be at least partially directed towards a target site in an eye. An optical coherence tomography (OCT) module and stereoscopic visualization camera are at least partially located in the head unit and configured to obtain a first set and a second set of volumetric data, respectively. A controller is configured to register the first set and second set of volumetric data to create a third set of registered volumetric data. The third set and second set of registered volumetric data are rendered, via a volumetric render module, to a first and second region. The first region and the second region are overlaid to obtain a shared composite view of the target site. The controller is configured to extract structural features and/or enable visualization of the target site.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
A61B 3/107 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining the shape or measuring the curvature of the cornea
An ophthalmic surgical instrument for peeling a retinal membrane is provided. The ophthalmic surgical instrument includes a handle, an actuator mounted to the handle, a first loop, and a second loop. The first loop extends outwardly from the handle and comprises a first plurality of protruding features configured to create an internal limiting membrane (ILM) flap in an eye. The second loop extends outwardly from the handle, is positioned within the first loop, and is configured to grasp the ILM flap. The actuator is configured to move the second loop to engage the first loop to grasp the ILM flap.
A mixer attachment for use with a surgical hand piece includes a powder plate configured to contain a solid substance for combining with a liquid substance to form a combined substance. The mixer attachment further includes a plurality of mixing plates configured to mix the solid substance and the liquid substance in the combined substance, the plurality of mixing plates including: one or more channeled plates comprising one or more channels and one or more through holes configured to facilitate turbulent flow of the combined substance during mixing, and one or more flat plates comprising a central opening to direct flow of the combined substance between the one or more channeled plates.
An Injection device (10) comprises an injection solution receptacle (30) and a plunger (70) at least a portion of which is slidably received in the injection solution receptacle (30), wherein the plunger (70) is displaceable relative to the injection solution receptacle (30) in a distal direction in order to expel an injection solution contained In the injection solution receptacle (30) from the injection solution receptacle (30). A first plunger stop mechanism (140) is adapted to stop a displacement of the plunger (70) relative to the injection solution receptacle (30) in the distal direction at a first dosing position (P1). A second plunger stop mechanism (140) is adapted to stop a displacement of the plunger (70) relative to the injection solution receptacle (30) from the first dosing position (P1) in the distal direction at a second dosing position (P2), wherein the first and the second dosing position (P2) of the plunger (70) are selected in such a manner that the plunger (70), upon being displaced relative to the Injection solution receptacle (30) between the first and the second dosing position (P2) Is adapted to expel a desired dose of the injection solution contained in the Injection solution receptacle (30) from the injection solution receptacle (30).
A stereoscopic imaging platform includes a stereoscopic camera configured to record left and right images of a target site. A robotic arm is operatively connected to the stereoscopic camera, the robotic arm being adapted to selectively move the stereoscopic camera relative to the target. The stereoscopic camera includes a lens assembly having at least one lens and defining a working distance. The lens assembly has at least one focus motor adapted to move the at least one lens to selectively vary the working distance. A controller is adapted to selectively execute one or more automatic focusing modes for the stereoscopic camera. The automatic focusing modes include a continuous autofocus mode adapted to maintain a focus of the at least one stereoscopic image while the robotic arm is moving the stereoscopic camera and the target site is moving along at least an axial direction.
H04N 23/959 - Computational photography systems, e.g. light-field imaging systems for extended depth of field imaging by adjusting depth of field during image capture, e.g. maximising or setting range based on scene characteristics
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G06T 7/593 - Depth or shape recovery from multiple images from stereo images
H04N 13/00 - Stereoscopic video systemsMulti-view video systemsDetails thereof
H04N 13/204 - Image signal generators using stereoscopic image cameras
An ophthalmic surgical instrument for measuring tissues is provided. The instrument includes a handle comprising a distal end and a proximal end, an instrument portion extending from the distal end of the handle, and an outer tube located around the instrument portion. The instrument portion of the surgical instrument further includes a distal end comprising an end effector. The degree of movement of the end effector corresponds to a scale on the handle of the surgical instrument that facilitates the measurement of a tissue during ophthalmic procedures. The movement of the outer tube or the end effector may further facilitate measurement of the tissue.
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
27.
3-(1-OXO-5-(PIPERIDIN-4-YL)ISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USES THEREOF
The present disclosure provides a compound of Formula (I):
The present disclosure provides a compound of Formula (I):
or a pharmaceutically acceptable salt hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, wherein R1, R2, R3, Rx, and n are as defined herein, and methods of making and using same.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The disclosure is directed to treatment regimens for treating Multiple Sclerosis (MS). These methods utilize administration of ofatumumab, an anti-CD20 monoclonal antibody, to the patient during a loading dose regimen and a maintenance regimen
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
29.
SUBSTITUTED INDOLE COMPOUNDS AND METHODS OF USE THEREOF
Provided herein are substituted indole compounds. In certain embodiments, the compounds are inhibitors of the alternative pathway of the complement system, and in particular, inhibitors of complement factor B (CFB). Also provided are compositions comprising the compounds and methods of use thereof. The compounds provided are useful in the treatment, prevention or amelioration of a disease, condition or disorder through inhibition of the complement alternative pathway.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
30.
METHODS AND SYSTEMS FOR MAXIMIZING OPHTHALMIC MEDICAL DEVICE UPTIME VIA PREDICTIVE HEALTH MONITORING AND PROACTIVE PREVENTATIVE MAINTENANCE
Certain aspects of the present disclosure provide techniques for predicting a likelihood of future failure of components in an ophthalmic medical device and performing preventative maintenance on the ophthalmic medical device. An example method generally includes receiving, from an ophthalmic medical device, measurements of one or more operational parameters associated with the ophthalmic medical device. Using one or more models, a future failure of the ophthalmic medical is predicted. The predictions are generated based, at least in part, on the received measurements of the one or more operational parameters. One or more actions are taken to perform preventative maintenance on the ophthalmic medical device based on the predicted future failure of the ophthalmic medical device.
G16H 40/40 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management of medical equipment or devices, e.g. scheduling maintenance or upgrades
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
G06Q 10/20 - Administration of product repair or maintenance
G06V 40/18 - Eye characteristics, e.g. of the iris
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 40/67 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
31.
ABLATION SYSTEMS AND METHODS FOR TREATING PRESBYOPIA
According to certain embodiments, an ophthalmic surgical system for treating presbyopia comprises controllable components and a computer. The controllable components comprise a light source that generates a light beam and a scanner that directs a focal point of the light beam. The computer determines an ablation profile to remove tissue from a central region and a peripheral region of a cornea of a first eye of a pair of eyes. The ablation profile is designed to remove tissue from the central region to yield a protrusion to provide for near-vision, and to remove tissue from the peripheral region to correct to emmetropia.
A method and device for reducing intraocular pressure in a patient. The method may comprise administering a viscoelastic material in Schlemm's canal to open aqueous humor outflow pathways. The device is adapted to perform the method. The viscoelastic material may be configured to lower the intraocular pressure within the eye.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The invention provides methods of using a population of CD19 CAR-expressing cells (for example, rapcabtagene autoleucel) for treating autoimmune diseases or disorders. Also disclosed are methods of making a population of CD19 CAR-expressing cells.
Provided herein are new crystalline form(s) of succinate salt(s) of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide (also known as ribociclib), pharmaceutical compositions comprising the same, methods of treatment using the same and methods of making the same.
The present invention relates to a method for measuring at least one inhalation flow feature in an inhaler, wherein a capsule containing a formulation is located in the inhaler, the method comprising the steps of sensing an impact feature relating to impacts of the capsule on the inhaler and correlating the impact feature to at least one inhalation flow feature. The present invention also relates to an inhaler adapted to aerosolize a formulation contained in a capsule, wherein the inhaler comprises a sensor for sensing an impact feature relating to impacts of the capsule on the inhaler and a processor for correlating the impact feature to at least one inhalation flow feature. The present invention also relates to a system comprising an inhaler adapted to aerosolize a formulation contained in a capsule and a computing device external of the inhaler, wherein the inhaler comprises a sensor for sensing an impact feature relating to impacts of the capsule on the inhaler and a data-receiving-transmitting means to receive and transmit data from and to the external computing device, wherein the external computing device also comprises data-receiving-transmitting means to receive and transmit data from and to the inhaler, wherein the inhaler and/or the external computing device comprises processing means for correlating the impact feature to at least one inhalation flow feature.
A system and method for selecting an intraocular lens, for implantation into an eye, includes a controller having a processor and a tangible, non-transitory memory on which instructions are recorded. The controller is configured to selectively execute a machine learning model trained with a training dataset. Execution of the instructions by the processor causes the controller to obtain pre-operative objective data for the patient, including one or more anatomic eye measurements. The controller is configured to obtain pre-operative questionnaire data for the patient, including at least one personality trait. The pre-operative objective data and the pre-operative questionnaire data are entered as respective inputs to the machine learning model. A predicted subjective outcome score for the patient is generated as an output of the machine learning model. The intraocular lens is selected based in part on the predicted subjective outcome score.
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/103 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining refraction, e.g. refractometers, skiascopes
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
38.
CARBAMOYLPHENYLBORONIC ACID-CONTAINING ACRYLIC MONOMERS AND USES THEREOF
The invention is generally related to an acrylamido monomer having one (carbamoylphenyl)boronic acid and a pKa of from about 6.4 to about 7.6 and to a water- soluble hydrophilic copolymers each comprising repeating units of such an acrylamido monomer.
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention pertains to expression vector designs for antibody constructs. Different polypeptide chains of an antibody construct are encoded within the same open reading frame, connected to each other by a 2A peptide linker. This expression vector design leads to homogeneous expression and correct assembly of the antibody construct.
The present invention relates to the field of pharmacy, particularly to a pharmaceutical composition for oral administration comprising a pharmaceutical composition for oral administration comprising: (a) an inert substrate, and (b) a mixture comprising N-(3-(6-amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, or a pharmaceutically acceptable salt thereof, or a free form thereof, and at least one binder. The present invention also relates to a process for preparing said pharmaceutical composition for oral administration; and to the use of said pharmaceutical composition in the manufacture of a medicament.
Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The invention is generally related to a class of water-soluble hydrophilic copolymers each of which comprises a small mole percentage of repeating monomeric units of at least one arylborono-containing vinylic monomer having a pKa of from about 6.4 to about 7.8 and a majority amount of repeating monomeric units of at least one hydrophilic vinylic monomer. The water-soluble hydrophilic copolymers can interact strongly and reversibly with membrane-bound mucins in the eye. When being used in an ophthalmic composition, they can function as a mucoadhesive hydrophilic polymer for prolonging the retention of demulcents and other drugs/comfort agents and also as active ingredients/lubricants due to their high hydrophilicity.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
48.
PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
49.
PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF IL-17 ANTIBODIES
The disclosure is directed to pharmaceutical products and stable liquid compositions of IL-17 antibodies and antigen-binding fragments thereof, e.g., AIN457 (secukinumab), and processes of making these pharmaceutical products and compositions. The disclosure is also directed to the use of these pharmaceutical products and liquid compositions (e.g., as part of a kit having instructions for use) for the treatment of various IL-17-mediated disorders (e.g., autoimmune disorders, such as psoriasis, ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis).
A system and method for assisting a surgeon performing an ophthalmic procedure on an eye of a patient, the system including a lubrication assembly. The lubrication assembly may include a mounting bracket, a dispenser, a lubricant source, a fluid line, and a first actuator. The dispenser is coupled to the mounting bracket which is configured to be coupled to a surgical microscope. The lubricant source is fluidly coupled to the dispenser by the fluid line for movement of a lubricant between the lubricant source and the dispenser. The first actuator dispenses the lubricant from the dispenser onto the eye of the patient.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61B 90/20 - Surgical microscopes characterised by non-optical aspects
51.
MUCOADHESIVE HYDROPHILIC COPOLYMERS AND USES THEREOF
The invention is generally related to a class of water-soluble hydrophilic copolymers each of which comprises a small mole percentage of repeating monomeric units of at least one arylborono-containing vinylic monomer having a pKa of from about 6.4 to about 7.8 and a majority amount of repeating monomeric units of at least one hydrophilic vinylic monomer. The water-soluble hydrophilic copolymers can interact strongly and reversibly with membrane-bound mucins in the eye. When being used in an ophthalmic composition, they can function as a mucoadhesive hydrophilic polymer for prolonging the retention of demulcents and other drugs/comfort agents and also as active ingredients/lubricants due to their high hydrophilicity.
C08F 230/06 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium or a metal containing a metal containing boron
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
52.
OPHTHALMIC LENS WITH PHASE-SHIFT STRUCTURE AND METHOD
An ophthalmic lens includes an optic with a first surface, a second surface, and a phase shift structure having one or more phase-shift regions. A method for fabricating an ophthalmic lens includes designing an optic with a first surface, a second surface, and a phase-shift structure having one or more phase-shift regions. The phase-shift regions may be adapted to generate respective chromatic focal shifts such that an incident radiation in a respective wavelength range at least partially converges towards a respective selected wavelength. The method includes determining a chromatic aberration target for the optic and determining the quantity of the phase-shift regions meeting the chromatic aberration target. The optic is formed with the phase-shift regions having respective optimal heights obtained based in part on an overall interaction effect. The phase-shift structure may be adapted to increase a depth-of-focus of the optic in the direction of extension.
Devices and methods are disclosed for improved removal of cortical material. In certain embodiments, an ophthalmic surgical instrument includes a shaft having a distal end configured to be inserted into an eye of a patient toward a treatment area, and a projection located at the distal end of the shaft, the projection having a distal surface that extends at an angle to a longitudinal axis of the shaft, the distal surface configured to be positioned facing the treatment area during use of the ophthalmic surgical instrument. The projection is located on a tip or a sleeve of the ophthalmic surgical instrument.
A61F 9/008 - Methods or devices for eye surgery using laser
A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
Certain embodiments disclosed herein provide systems and methods for coupling an optical fiber to a ferrule. For example, certain aspects provide a method for coupling an optical fiber to a ferrule including inserting the optical fiber through a ferrule such that an end of the optical fiber protrudes beyond an end of the ferrule and applying a laser beam to the end of the optical fiber, wherein the laser beam melts a portion of the optical fiber. The method further includes securing, through cooling of the melted portion of the optical fiber, the optical fiber to the ferrule, wherein the laser beam melts a portion of the optical fiber to create a fluid which seals the optical fiber to the ferrule upon solidifying.
F21V 8/00 - Use of light guides, e.g. fibre optic devices, in lighting devices or systems
A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor
A61F 9/008 - Methods or devices for eye surgery using laser
A system and method for assisting a surgeon performing an ophthalmic procedure on an eye of a patient, the system including a lubrication assembly. The lubrication assembly (104) may include a mounting bracket (140), a dispenser (142), a lubricant source (146), a fluid line (144), and a first actuator (148). The dispenser (142) is coupled to the mounting bracket (140) which is configured to be coupled to a surgical microscope. The lubricant source (146) is fluidly coupled to the dispenser (142) by the fluid line (144) for movement of a lubricant between the lubricant source (146) and the dispenser (142). The first actuator (148) dispenses the lubricant from the dispenser (142) onto the eye (180) of the patient.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present disclosure relates to compounds of formula (I) and pharmaceutical compositions and their use in reducing Widely Interspaced Zinc Finger Motifs (WIZ) expression levels, or inducing fetal hemoglobin (HbF) expression, and in the treatment of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta-hemoglobinopathies), such as sickle cell disease and beta-thalassemia.
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/5383 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
C07D 451/02 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof
The present invention provides a compound of Formula (I):
The present invention provides a compound of Formula (I):
or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds; and methods of using such compounds for treating a disease or condition mediated by nuclear SET domain-containing protein 2 (NSD2).
The invention is generally related to an acrylamido monomer having one (carbamoylphenyl)boronic acid and a pKa of from about 6.4 to about 7.6 and to a water-soluble hydrophilic copolymers each comprising repeating units of such an acrylamido monomer.
C08L 85/02 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbonCompositions of derivatives of such polymers containing phosphorus
C08L 85/04 - Compositions of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing atoms other than silicon, sulfur, nitrogen, oxygen, and carbonCompositions of derivatives of such polymers containing boron
60.
OCULAR IMPLANTS FOR DELIVERY INTO AN ANTERIOR CHAMBER OF THE EYE
An ocular implant adapted to be disposed within Schlemm's canal of a human eye with a body extending along a curved longitudinal central axis in a curvature plane, a first strut on one side of the implant and a second strut on an opposite side of the implant, the circumferential extent of the first strut with respect to the plane of curvature being greater than the circumferential extent of the second strut with respect to the plane of curvature. The invention also includes methods of using the implant.
A system includes a controller with at least one processor and at least one non-transitory, tangible memory on which instructions are recorded for executing a method for obtaining a profile of a lens capsule of an eye. The profile is represented by respective central surfaces and respective equatorial surfaces separated at respective transition points. The controller is configured to obtain imaging data for a portion of the lens capsule visible through a pupil of the eye. The imaging data is transformed to an adjusted frame of reference and fitted to the respective central surfaces in a predefined central region of the lens capsule. The profile is obtained based on a set of fitting parameters for the respective central and equatorial surfaces. The respective central surfaces and respective equatorial surfaces may be represented as elliptical cones and skewed parabolas, respectively.
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/10 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions
A61B 3/117 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for examining the anterior chamber or the anterior chamber angle, e.g. gonioscopes
A61B 3/14 - Arrangements specially adapted for eye photography
Devices and methods are disclosed for improved removal of cortical material. In certain embodiments, an ophthalmic surgical instrument includes a shaft having a distal end configured to be inserted into an eye of a patient toward a treatment area, and a projection located at the distal end of the shaft, the projection having a distal surface that extends at an angle to a longitudinal axis of the shaft, the distal surface configured to be positioned facing the treatment area during use of the ophthalmic surgical instrument. The projection is located on a tip or a sleeve of the ophthalmic surgical instrument.
Described herein is a crystalline hydrate form of LNP023 hydrochloride and to a process for its preparation. Furthermore, described herein is a pharmaceutical composition comprising the crystalline hydrate form of LNP023 hydrochloride, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition described herein can be used to treat a disease and disorder mediated by complement activation.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
In some embodiments, an ophthalmic surgical feedback system includes a laser device configured to emit light to a location on eye tissue of a patient and generate biomechanics information for the location based on the light. The ophthalmic surgical feedback system also includes a memory having executable instructions and a processor in communication with the laser device and the memory. The processor is configured to execute the instructions to determine strength of the eye tissue at the location based on the biomechanics information. The processor is further configured to execute the instructions to generate feedback related to utilization of a surgical instrument at the location based on the determined strength.
A cannula with an augmented frictional surface to enhance physical security thereof. The augmented surface may be of unique morphology with rows or ribs. The ribs may be continuons or individual projections. They may be horizontal or screw-like. In one embodiment of screw-like ribs, rotations during placement and removal of the cannula may be employed.
A transscleral illuminator includes a base and an optical fiber. The base has a geometry that is based on at least two cannulas inserted in a pars plana of a human eye. The base includes an inferior surface and a superior surface. The inferior surface is configured to interface with an external portion of the human eye. The optical fiber is disposed in the base and configured to transmit light through the base and the external portion of the human eye to illuminate an internal portion of the human eye.
Disclosed are ophthalmic lenses, ophthalmic lens components, and methods, systems, and apparatus for manufacturing an ophthalmic lens component. In one aspect, disclosed is an intraocular lens, comprising an optic portion and a haptic coupled to the optic portion. The haptic can comprise a haptic anterior portion and a haptic posterior portion. The haptic anterior portion can have an anterior surface roughness and the haptic posterior portion can have a posterior surface roughness. The posterior surface roughness can be greater than the anterior surface roughness such that at least part of the haptic anterior portion is smoother than the haptic posterior portion.
This application relates to various anhydrous crystalline forms N-(3-(6-Amino-5-(2-(N-methylacrylamido)ethoxy)pyrimidin-4-yl)-5-fluoro-2-methylphenyl)-4-cyclopropyl-2-fluorobenzamide, as well as compositions, method of making and methods of using the same. These crystalline forms are useful in the treatment of diseases and disorders which are typically ameliorated by the inhibition of BTK. Such diseases and disorders may include inflammatory and autoimmune disorders and pulmonary and respiratory tract inflammation.
The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I):
The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I):
The present invention relates to novel pyridazin-3-yl phenol compounds of Formula (I):
wherein R1, R2, R3, R4, R5 and Z are defined herein, which inhibit NOD-like receptor protein 3 (NLRP3) inflammasome activity. The invention further relates to the processes for their preparation, pharmaceutical compositions and medicaments containing them, and their use in the treatment of diseases and disorders mediated by NLRP3.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 451/04 - Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamineCyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring systems, e.g. tropaneCyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.02,4] nonane ring system
71.
INTELLIGENT DETECTION AND TREATMENT OF ISCHEMIC TISSUE
In an embodiment, a surgical system for treating ischemic tissue includes an oxygenation sensor, a laser source operable to emit treatment laser light, and a processor in communication with the oxygenation sensor and the laser source. The processor is operable to cause the oxygenation sensor to detect an oxygenation status of a tissue based on illumination light reflected from the tissue. The processor is further operable to generate a feedback signal related to utilization of the laser source in relation to the tissue based on the oxygenation status. Other embodiments of this aspect include corresponding computer systems, apparatus, and computer programs recorded on one or more computer storage devices, each configured to perform the actions of the methods.
In certain embodiments, a system for predictive vision biometrics includes an ophthalmic multispectral imaging device, a memory including executable instructions, and a processor in communication with the memory and the ophthalmic multispectral imaging device. The ophthalmic multispectral imaging device is configured to generate ophthalmic multispectral data for a patient eye. The processor is configured to execute the instructions to determine a state of an eye condition in the patient eye based on the ophthalmic multispectral data, and to simulate one or more treatment scenarios for the patient eye based on the state of the eye condition and a model for the one or treatment scenarios.
Certain embodiments disclosed herein provide systems and methods for coupling an optical fiber to a ferrule. For example, certain aspects provide a method for coupling an optical fiber to a ferrule including inserting the optical fiber through a ferrule such that an end of the optical fiber protrudes beyond an end of the ferrule and applying a laser beam to the end of the optical fiber, wherein the laser beam melts a portion of the optical fiber. The method further includes securing, through cooling of the melted portion of the optical fiber, the optical fiber to the ferrule, wherein the laser beam melts a portion of the optical fiber to create a fluid which seals the optical fiber to the ferrule upon solidifying.
A method for reducing blue light toxicity during an eye surgery includes producing warm white light via a lighting source, the warm white light having a color temperature of less than about 4500° Kelvin and excluding wavelengths falling within a range of 380 nanometers (nm) to 450 nm, such that the blue light toxicity is reduced during the eye surgery. The method includes illuminating a pupil and iris of the eye with the warm white light during the eye surgery and collecting digital images of the eye using a digital camera. Within the images, a processor selectively adjusts a characteristic of constituent pixels comprising an iris pixel region or a pupil pixel region of the eye to provide an enhanced characteristic. The method may be performed by executing instructions from a computer-readable storage medium at predetermined stages of an eye surgery.
A61B 3/14 - Arrangements specially adapted for eye photography
H04N 23/88 - Camera processing pipelinesComponents thereof for processing colour signals for colour balance, e.g. white-balance circuits or colour temperature control
75.
INTELLIGENT DETECTION AND TREATMENT OF ISCHEMIC TISSUE
In an embodiment, a surgical system for treating ischemic tissue includes an oxygenation sensor, a laser source operable to emit treatment laser light, and a processor in communication with the oxygenation sensor and the laser source. The processor is operable to cause the oxygenation sensor to detect an oxygenation status of a tissue based on illumination light reflected from the tissue. The processor is further operable to generate a feedback signal related to utilization of the laser source in relation to the tissue based on the oxygenation status. Other embodiments of this aspect include corresponding computer systems, apparatus, and computer programs recorded on one or more computer storage devices, each configured to perform the actions of the methods.
In certain embodiments, a system for predictive vision biometrics includes an ophthalmic multispectral imaging device, a memory including executable instructions, and a processor in communication with the memory and the ophthalmic multispectral imaging device. The ophthalmic multispectral imaging device is configured to generate ophthalmic multispectral data for a patient eye. The processor is configured to execute the instructions to determine a state of an eye condition in the patient eye based on the ophthalmic multispectral data, and to simulate one or more treatment scenarios for the patient eye based on the state of the eye condition and a model for the one or treatment scenarios.
A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
A61B 3/12 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for looking at the eye fundus, e.g. ophthalmoscopes
A61B 3/14 - Arrangements specially adapted for eye photography
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
A transscleral illuminator includes a base and an optical fiber. The base has a geometry that is based on at least two cannulas inserted in a pars plana of a human eye. The base includes an inferior surface and a superior surface. The inferior surface is configured to interface with an external portion of the human eye. The optical fiber is disposed in the base and configured to transmit light through the base and the external portion of the human eye to illuminate an internal portion of the human eye.
In certain embodiments, an ophthalmic laser system includes a laser system, imaging system, and computer. The laser system accesses a planned test pattern of planned laser spots and directs a laser beam towards a test target located at a target plane according to the planned test pattern to yield an actual test pattern of actual laser spots on the test target. The actual laser spots correspond to the planned laser spots. The imaging system has a digital camera that generates a digital image of the actual test pattern. The computer analyzes the digital image to: compare the actual test pattern to the planned test pattern; detect a deviation of the actual from the planned test pattern; identify an issue indicated by the deviation; and provide output in response to the identified issue.
In some embodiments, an ophthalmic surgical feedback system includes a laser device configured to emit light to a location on eye tissue of a patient and generate biomechanics information for the location based on the light. The ophthalmic surgical feedback system also includes a memory having executable instructions and a processor in communication with the laser device and the memory. The processor is configured to execute the instructions to determine strength of the eye tissue at the location based on the biomechanics information. The processor is further configured to execute the instructions to generate feedback related to utilization of a surgical instrument at the location based on the determined strength.
Optical systems for forming uniform illumination are disclosed. The optical system includes a light source coupled to a plurality of first light carriers providing a plurality of light intensities and a second light carrier coupled to the plurality of first light carriers. The second light carrier spatially homogenizes the plurality of light intensities to form a homogenized light intensity. The optical system further includes an illumination module coupled to the second light carrier and operable to receive the homogenized light intensity.
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable software for healthcare professionals for the
provision of information about radioligand therapies;
downloadable software for healthcare professionals for
placement of product orders, administration and tracking of
product orders in the field of radioligand therapies. Providing medical information related to radioligand therapy
via the Internet or downloadable software applications.
82.
SYSTEMS AND METHODS FOR CREATING A LENTICULE FOR PRESBYOPIA
In certain embodiments, an ophthalmic surgical system for creating a lenticule in the cornea of an eye comprises controllable components (including a laser source and a scanner) and a computer. The laser source generates a laser beam, and the scanner directs the focal point of the laser beam. The computer determines a lenticule design for the lenticule having a posterior side and an anterior side. Either the posterior side or the anterior side has a central portion and a peripheral portion. The lenticule design is formed using a major lenslet and a minor lenslet, where the major lenslet is designed to correct to emmetropia. The lenticule design is formed by subtracting the minor lenslet from the major lenslet, where the subtraction of the minor lenslet yields the central portion. The computer instructs one or more of the controllable components to create the lenticule.
In certain embodiments, an ophthalmic laser system includes a laser system, imaging system, and computer. The laser system accesses a planned test pattern of planned laser spots and directs a laser beam towards a test target located at a target plane according to the planned test pattern to yield an actual test pattern of actual laser spots on the test target. The actual laser spots correspond to the planned laser spots. The imaging system has a digital camera that generates a digital image of the actual test pattern. The computer analyzes the digital image to: compare the actual test pattern to the planned test pattern; detect a deviation of the actual from the planned test pattern; identify an issue indicated by the deviation; and provide output in response to the identified issue.
In certain embodiments, an ophthalmic laser system include a laser system, imaging system, and computer. The laser system accesses a planned test pattern of a planned laser spot having a planned beam feature and directs a laser beam towards a test target located at a target plane according to the planned test pattern to yield an actual test pattern of an actual laser spot having an actual beam feature. The imaging system includes one or more digital cameras that generate a digital image of the actual test pattern of the actual laser spot. The computer analyzes the digital image to compare the actual laser spot to the planned laser spot, to detect a deviation of the actual beam feature from the planned beam feature, to identify an issue indicated by the deviation, and to provide output in response to the issue.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, medical and veterinary preparations, sanitary preparations for medical purposes, pharmaceutical preparations for pain relief, topical analgesics, topical anti-inflammatories, adhesive patches for medical purposes, adhesive patches incorporating pharmaceutical preparations, dietetic food and substances adapted for medical or veterinary use, food for babies, dietary supplements for humans and animals, plasters, materials for dressings, material for stopping teeth, dental wax, disinfectants, preparations for destroying vermin, fungicides, herbicides.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical, medical and veterinary preparations, sanitary preparations for medical purposes, pharmaceutical preparations for pain relief, topical analgesics, topical anti-inflammatories, adhesive patches for medical purposes, adhesive patches incorporating pharmaceutical preparations, dietetic food and substances adapted for medical or veterinary use, food for babies, dietary supplements for humans and animals, plasters, materials for dressings, material for stopping teeth, dental wax, disinfectants, preparations for destroying vermin, fungicides, herbicides.
S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
Disclosed are ophthalmic lenses, ophthalmic lens components, and methods, systems, and apparatus for manufacturing an ophthalmic lens component. In one aspect, disclosed is an intraocular lens, comprising an optic portion and a haptic coupled to the optic portion. The haptic can comprise a haptic anterior portion and a haptic posterior portion. The haptic anterior portion can have an anterior surface roughness and the haptic posterior portion can have a posterior surface roughness. The posterior surface roughness can be greater than the anterior surface roughness such that at least part of the haptic anterior portion is smoother than the haptic posterior portion.
In certain embodiments, ophthalmic laser system includes an auxiliary light system, laser system, imaging system, and computer. The auxiliary light system directs auxiliary light towards a test target according to a planned test pattern to yield one or more actual auxiliary spots of an actual test pattern on the test target. The planned test pattern indicates one or more planned auxiliary spots located relative to a planned laser spot in a predetermined manner. The laser system directs a laser beam to yield an actual laser spot of the actual test pattern on the test target. The imaging system generates a digital image of the actual test pattern. The computer analyzes the digital image to compare the actual to the planned test pattern, detect a deviation of the actual from the planned test pattern, identify an issue indicated by the deviation, and provide output in response to the issue.
Optical systems for forming uniform illumination are disclosed. The optical system includes a light source coupled to a plurality of first light carriers providing a plurality of light intensities and a second light carrier coupled to the plurality of first light carriers. The second light carrier spatially homogenizes the plurality of light intensities to form a homogenized light intensity. The optical system further includes an illumination module coupled to the second light carrier and operable to receive the homogenized light intensity.
Described herein are methods of treating ANCA-associated vasculitis (AAV) with the Factor B inhibitor iptacopan or a pharmaceutically acceptable salt thereof, e.g., iptacopan hydrochloride, or hydrate thereof.
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
09 - Scientific and electric apparatus and instruments
42 - Scientific, technological and industrial services, research and design
Goods & Services
Downloadable software in the nature of a mobile application for providing information related to detection of counterfeit, falsified and illegal pharmaceutical products; infrared detectors; counterfeit pharmaceutical product detector. Providing temporary use of a non-downloadable web application for processing information related to authentication services; authenticating pharmaceutical products.
09 - Scientific and electric apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable software for healthcare professionals for the
provision of information about radioligand therapies;
downloadable software for healthcare professionals for
placement of product orders, administration and tracking of
product orders in the field of radioligand therapies. Providing medical information related to radioligand therapy
via the Internet or downloadable software applications.
The present invention pertains to the use of gene editing and miRNA technologies for improving recombinant production of ANGPTL3 mimetics in CHO cells. The gene expression modifications are used for knock-out/knock-down of the endogenous protein CCL2 of the CHO cells which is difficult to separate from ANGPTL3 mimetics during purification.
